

## NUCALA (MEPOLIZUMAB) ORDER FORM

### PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

Mobile Number: \_\_\_\_\_ Patient Weight: \_\_\_\_\_

Allergies: \_\_\_\_\_

### DIAGNOSIS (Provider must specify)

- Severe asthma (age 6+):  J45.50  J45.52  J45.51     Hypereosinophilic syndrome: D72.119  
 Chronic rhinosinusitis w/ nasal polyps: J.33.8     Other: \_\_\_\_\_  
 Eosinophilic granulomatosis w/ polyangiitis: M30.1

### PROVIDER INFORMATION

Provider Name (print name): \_\_\_\_\_ Provider NPI: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

Email Address: \_\_\_\_\_

**Prerequisites to treatment** – ensure the following information is complete and attached with referral:

- Demographics     Labs and tests supporting diagnosis     Office/progress notes

### PRE-MEDICATION (Not typically indicated)

- Acetaminophen (Tylenol) 500 mg PO     Famotidine 20 mg IV     Methylprednisolone (Solu-Medrol) 125 mg IVP  
 Benadryl 25mg PO     Cetirizine (Zyrtec) 10 mg PO  
 Other: \_\_\_\_\_ Dose: \_\_\_\_\_ Route: \_\_\_\_\_

### MEDICATION

MEDICATION	DOSE	ROUTE	FREQUENCY
Nucala	<input type="checkbox"/> 100mg <input type="checkbox"/> 40mg <input type="checkbox"/> 300mg <input type="checkbox"/> 300mg	<input type="checkbox"/> Subcutaneous Inj	<input type="checkbox"/> Every 4 weeks

New Start Therapy     Continuation of Therapy    Date of last dose (if applicable): \_\_\_\_\_

### LABS / SPECIAL INSTRUCTIONS

**FAX NUMBERS:**  NH: 603.217.5371     ME: 207.407.7272

Order valid for 1 year from date of signature unless otherwise specified here: \_\_\_\_\_